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Abstract Neuropathic vulvodynia is a state of vulval discom-
fort characterized by a burning sensation, diffuse pain, pruritus
or rawness with an acute or chronic onset. Diabetes mellitus
may cause this type of vulvar pain in several ways, so this
study was conducted to evaluate streptozotocin-induced dia-
betes as a neuropathic pain model for vulvodynia in female
rats. The presence of streptozotocin (50 mg/kg i.p.)-induced
diabetes was initially verified by disclosure of pancreatic tis-
sue degeneration, blood glucose elevation and body weight
loss 5–29 days after a single treatment. Dynamic (shortened
paw withdrawal latency to light brushing) and static (dimin-
ished von Frey filament threshold pressure) mechanical
allodynia was then confirmed on the plantar foot surface. Sub-
sequently, both static and dynamic vulvodynia was detected
by application of the paradigm to the vulval region. Systemic
gabapentin (75 mg/kg, i.p.) and topical gabapentin (10 % gel)
were finally tested against allodynia and vulvodynia. Topical
gabapentin and the control gel vehicle significantly increased
paw withdrawal threshold in the case of the static allodynia
model and also paw withdrawal latency in the model for dy-
namic allodynia when compared with the streptozotocin-
pretreated group. Likewise, in the case of static and dynamic
vulvodynia, there was a significant antivulvodynia effect of
systemic and topical gabapentin treatment. These outcomes
substantiate the value of this model not only for allodynia but
also for vulvodynia, and this was corroborated by the findings
not only with systemic but also with topical gabapentin.
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Introduction
The prevalence of diabetes mellitus has been increasing glob-
ally, and it was estimated by the WHO that the occurrence of
diabetes in adults was 173 million in 2002 (Shaw et al. 2010).
Painful diabetic neuropathy is a complication of diabetes
mellitus, and it is encountered in 60 % of patients adversely
affecting their quality of life (Said 2007). In neuropathic pain,
spontaneous and pathologically exaggerated responses occur
to noxious and non-noxious stimuli (Costigan et al. 2009).
Underlying mechanisms implicated in neuropathic pain include
synaptic facilitation which contributes to secondary hypersen-
sitivity and tactile allodynia (Campbell and Meyer 2006).
Vulvodynia is a state of vulval discomfort characterized by
burning, diffuse moderate to severe pain, pruritus or rawness
with acute or chronic onset. Usually, there are few visible
symptoms, although varying degrees of erythema have been
reported (Bachmann et al. 2006; Lynch 1986; Paavonen 1995;
Young et al. 1984), and the most frequently identified types
are generalized unprovoked vulvodynia or vestibulodynia
(Backonja et al. 1998). Diabetes mellitus may cause vulvar
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pain of this type in several ways (Kalra et al. 2013), and
currently, the management of neuropathic pain involves ad-
junctive therapy. It is a challenge to define an exact course of
treatment for instance in diabetic neuropathy since active pain
mechanisms in patients are still not clearly defined and often
expressed as complex pain phenotypes. Consequently, only
partial relief is achievable in most individuals (Goodnick
et al. 2000; Field et al. 1999). It has been shown that diabetic
and para-diabetic neuropathic pain is invariably resistant to
classical non-steroidal anti-inflammatory drugs (NSAIDs)
and opioids or that it has a poor response to these agents
(James and Page 1994).
In this connection, numerous drugs have been extensively
investigated against painful diabetic neuropathy including
gabapentin (Gorson et al. 1999; Field et al. 1999; Zhang
et al. 2013). Moreover, analgesic antidepressants have also
been shown to promote the responsiveness of neurons in the
locus coeruleus to noxious stimulation in a chronic neuropa-
thy model (Alba-Delgado et al. 2012) though gabapentin has
not been studied in this respect. An earlier retrospective clin-
ical study concluded that topical gabapentin may be useful in
neuropathic pain including allodynia in the area of the vulva
(vulvodynia) (Boardman et al. 2008). Gabapentin
[1-(aminomethyl) cyclohexane acetic acid] is an antiepileptic
drug and structural analogue of the neurotransmitter gamma-
aminobutyric acid (GABA). It was introduced in 1993 by the
US FDA as an adjuvant anticonvulsant (Barrueto et al. 2002)
and subsequently for various chronic pain conditions includ-
ing diabetic neuropathy (Apkarian et al. 2009; Bennett and
Simpson 2004; Gilron 2007; Gilron et al. 2005; Hunter et al.
1997; Mao and Chen 2000; Wiffen et al. 2005; Leo 2013). In
this context, analgesic effects on peripheral nociception in rats
have been reported to injectable gabapentin (Carlton and Zhou
1998; Cesena and Calcutt 1999).
The primary aim of the study was to employ a
streptozotocin-induced neuropathic pain model to establish
the existence of mechanical allodynia and then to investigate
the presence of any potential static or dynamic mechanical
vulvodynia. Subsequently, the objective was to evaluate the
activity of gabapentin either administered systemically or ap-
plied locally as a topical gel preparation against vulvodynia as
a mode of further validating the model for predicting rele-
vance to the clinic (Bates and Timmins 2002).
Methods and materials
Chemicals and instruments
A von Frey filament (hair) kit was obtained from Stoelting
(USA). The following were purchased from suppliers:
streptozotocin (Sigma-Aldrich), glucometer (Roche Diagnos-
tic Corporation, Germany), blood glucose strips (Optium
Xceed, Abbott), gabapentin gel 10 % w/w and the control
gel base (a liposome-containing oil in water gel comprising
xanthan gum hydrocolloid with polyacrylamide) minus the
active pharmaceutical ingredient [API]) were supplied by St
Mary’s Pharmaceutical Unit (SMPU, Cardiff, UK) under their
Manufacturer’s Special License (MS). Gabapentin was ob-
tained from MKB Pharmaceuticals (Pvt.) Ltd., Peshawar, Pa-
kistan. All other chemicals and reagents used were of analyt-
ical grade.
Animals
Sprague-Dawley female rats, bred in the animal house and
bioassay laboratories of the Department of Pharmacy, Univer-
sity of Peshawar, were used throughout experimental studies.
Animals were housed in transparent cages with free access to
standard laboratory food and water available ad libitum. All
experimental procedures were carried out between 0800 and
1700 h. A 12–12-h light and dark cycle was provided with an
ambient temperature maintained at 22.0±2.0 °C through a
reversible air conditioning system.
Ethical approval
The study of the topical gabapentin application was approved
under a project entitled ‘Studies on the effects of topical for-
mulations of different analgesics on allodynia and vulvodynia
components of diabetic neuropathic pain’ by the Ethical Com-
mittee of the Department of Pharmacy, University of Pesha-
war, Peshawar, Khyber Pakhtunkhwa (KP), Pakistan, who
issued approval certificate no 13/EC-12/Pharm. The study of
systemic gabapentin administration was approved under a
project entitled ‘Evaluation of the anti-inflammatory,
antinociceptive and antipyretic activities of selected synthetic
and natural compounds in animal models’ (approval certifi-
cate no 15/EC/Pharm). Moreover, all animal procedures were
conducted strictly according to the Animals Scientific Proce-
dure Act (1986) of UK.
Induction of diabetes
Female Sprague-Dawley rats, weighing 175–200 g (age
range=7.0±1.0 weeks), were randomly divided into saline
vehicle and treatment groups. Sixteen hours after fasting (Ba-
bu et al. 2003), animals were weighed and a single intraperi-
toneal (i.p.) injection of streptozotocin (STZ) (50 mg/kg) was
administered for the induction of diabetes (Field et al. 1999).
Since streptozotocin has a stability problem (Rakieten et al.
1963), fresh solutions were prepared for each period of ad-
ministration. Sixty minutes after streptozotocin administra-
tion, animals were allowed free access to food and water and
then kept under close observation for the next 5 days during
the development of diabetic symptoms. To maintain
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cleanliness and avoid development of any infection due to
excessive urination, animal bedding was changed frequently.
The singly administered dose of streptozotocin in our study
was lower than that employed by other research groups in rats
(Indolfi et al. 2001; Wei et al. 2003) and was in point of fact
only half of that given by Indolfi et al. (2001). Additionally, at
the 50 mg/kg streptozotocin dose level, no undue adverse
behavioural effects have been previously reported (Field
et al. 1999; Jolivalt et al. 2006). Consequently, the degree of
insulinopoenia in this study was not supplemented by exoge-
nous insulin administration, and this has been corroborated by
chronological survival rates even up to 6-fold longer than our
study duration (Wei et al. 2003).
Measurement of blood glucose and body weight
Blood glucose levels of animals were measured at
predetermined time intervals, i.e. experimental days 0, 5, 15
and 29 using a glucometer (Roche Diagnostic Corporation,
Germany). Blood samples were collected from the rats by
the tail tip method. Body weights of the diabetic and saline-
treated animals were also recorded throughout the experimen-
tal protocol.
Assessment of static allodynia in diabetic female rats
Pretreatment schedule
On the 29th day post-streptozotocin administration, animals
were acclimatized to cages with wire mesh bottoms for 15–
45 min. A series of von Frey filaments (0.4, 0.6, 1, 1.4, 2, 4, 6,
8, 10 and 15 g) were applied perpendicularly to the mid-
plantar surface of the right hind paw to an extent that caused
the hairs to bend (Calcutt and Chaplan 2009). Each von Frey
filament was applied for a period of up to 6 s as a cut-off time
or until an escape response (paw withdrawal threshold (PWT)
or licking) occurred. The withdrawal threshold was defined as
the minimum applied force (g±SD) required to induce a paw
withdrawal reflex (Field et al. 1999). Lifting of the paw or
licking was recorded as a positive response, and a succeeding
von Frey filament of lower force was applied for the following
recording. However, in the case of an absence of response, the
subsequent von Frey filament of higher force was applied.
This procedure was continued until four measurements were
taken after an initial change including the first one, in response
(positive response) or five consecutive negative responses (2,
4, 6, 8 and 10-g force) or four consecutive positive responses
(1.4, 1, 0.6 and 0.4-g force). A force of 15gwas selected as the
cut-off force at which point further application ceased. von
Frey filaments were applied at intervals of several seconds
in order to avoid any influence of previous stimuli on behav-
iour. Any ambulation was noted as an indefinite response, and
the stimulus was repeated. Static allodynia was indicated by a
reduced force required to induce a paw withdrawal reflex.
Post-treatment schedule
Animals included for the post-drug-treatment study were
thosewhich exhibited amean response of ≤3.63g (see Table 1)
(Field et al. 1999). In the topical gabapentin investigation, a
uniform amount of 10 % gabapentin gel (1.0 mL/cm2) was
applied topically for three times daily (0800, 1200 and 1600 h)
on the plantar surface of the right hind paw. Static
allodynia was measured 1 h post-drug application. The con-
centration of gabapentin applied in the form of gel (i.e.
100 mg/cm2) was 3.3-fold higher than that previously
employed for topical lidocaine in hypoalgesic studies on mu-
cous membranes (Schønemann et al. 1992). Control animals
received an equivalent application of control gel (1.0 mL/
cm2). In the case of the systemic study, gabapentin (75 mg/kg,
i.p.) was administered to animals meeting the selection crite-
rion, and static allodynia was measured at 1 and 2 h post-drug
administration. Control animals received an equivalent
amount of normal saline vehicle. The von Frey PWT inclusion
criterion for static vulvodynia is shown in Table 1. The overall
mean PWT values were calculated from the pooled
post-treatment triplicate daytime readings (0800, 1200
and 1600 h) of static allodynia in the topical study or the
duplicate readings (1 and 2 h) post-administration in the
systemic study.
Assessment of dynamic allodynia in diabetic female rats
On the 29th day post-streptozotocin injection, dynamic
allodynia was assessed by lightly brushing the plantar surface
of the hind paw of each animal with a cotton bud. The time to
flinching or licking of the paw was regarded as the paw with-
drawal latency (PWL) in seconds. Animals responding to the
cotton bud within 8 s were selected for the study (Field et al.
1999). Fifteen seconds was selected as cut-off time beyond
which the assessment was terminated.
In the topical study, gabapentin gel (10 %; 100 mg/cm2) or
control gel (1.0 mL/cm2) was then applied to the hind paw,
three times daily (0800, 1200 and 16.00 h), and animals
Table 1 Inclusion criteria for static and dynamic allodynia or
vulvodynia
Static
allodynia
Dynamic allodynia Static vulvodynia Dynamic
vulvodynia
≤3.63-g von
Frey paw
withdrawal
threshold
(PWT)
≤8.0-s brushing
paw withdrawal
latency (PWL)
≤0.16-g von
Frey flinching
response
threshold
(FRT)
≤4.0-s brushing
flinching
response
latency (FRL)
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were tested for dynamic allodynia, by the method described
above, 1 h post-gabapentin gel or control gel application.
Systemic gabapentin (75 mg/kg, i.p) was administered and
dynamic allodynia was measured by the method described
above at 1 and 2 h post-drug administration. The brushing
PWL inclusion criterion for dynamic allodynia is shown in
Table 1. The overall mean PWL values were calculated from
the pooled post-treatment triplicate daytime readings (08.00,
12.00 and 16.00 h) of dynamic allodynia in the topical study
or the duplicate readings (1 and 2 h) post-administration in the
systemic study.
Assessment of static vulvodynia in diabetic female rats
Pretreatment schedule
The anogenital area including the mons pubis area of female
rats was carefully shaved. The animals were then acclimatized
to cages with wire mesh bottoms for 15–45 min (to prevent
excessive exploration and major grooming activities). A series
of von Frey filaments (0.008, 0.02, 0.04, 0.07, 0.16, 0.4, 0.6
and 1.0 g) were applied perpendicularly for a period of 4 s and
the flinching response threshold (FRT, g) recorded. This pro-
cedure was continued for up to four measurements after an
initial change in response (positive response) or five consec-
utive negative responses (0.07, 0.16, 0.4, 0.6 and 1-g force) or
two consecutive positive responses (0.008 and 0.02-g force).
Ambulation was noted as an ambiguous response, and if it
occurred, the stimulus was repeated. A von Frey force of 1g
was selected as the cut-off beyond which the assessment was
terminated.
Post-treatment schedule
On the 29th day post-streptozotocin administration, a stan-
dardized testing paradigm (Chaplan et al. 1994) was used
with modifications for the vulvodynia study. The von Frey
FRT inclusion criterion for static vulvodynia is shown in
Table 1.
Gabapentin gel (10 %; 100 mg/cm2) was then applied top-
ically for three times daily (0800, 1200 and 1600 h) to the
anogenital region. Static vulvodynia was assessed 1 h after
gabapentin gel application. Control gel (1.0 mL/cm2) was ap-
plied in the control animal group. Systemic gabapentin
(75 mg/kg, i.p) was administered, and static vulvodynia was
measured by the method described above at 1 and 2 h post-
drug administration, the controls receiving an equivalent
amount of i.p. normal saline. The overall mean FRT values
were calculated from the pooled post-treatment triplicate day-
time readings (800, 1200 and 1600 h) of static vulvodynia in
the topical study or the duplicate readings (1 and 2 h) post-
administration in the systemic study.
Assessment of dynamic vulvodynia in diabetic rats
The anogenital area of animals was shaved as before. The
animals were then acclimatized on wire mesh cages for 15–
45 min. On the 29th day post-streptozotocin administration,
dynamic vulvodynia was assessed by lightly brushing the
anogenital region for a period of 10 s or until a flinching
response occurred (flinching response latency (FRL)). If no
response occurred within 10 s (cut-off time), then the proce-
dure was terminated and the animal was excluded from the
study. The brushing FRL inclusion criterion for dynamic
vulvodynia is shown in Table 1.
Animals meeting the inclusion criteria in the topical study
had gabapentin gel (10 %; 100 mg/cm2) or control gel
(1.0 mL/cm2) applied for three times daily (0800, 1200 and
1600 h) and were tested for dynamic vulvodynia 1 h later.
Systemic gabapentin (75 mg/kg, i.p) was administered, and
animals were tested for dynamic vulvodynia by the method
described above at 1 and 2 h post-drug administration, the
controls receiving an equivalent amount of i.p. normal saline.
The overall mean FRL values were calculated from the pooled
post-treatment triplicate daytime readings (0800, 1200 and
1600 h) of dynamic vulvodynia in the topical study or the
duplicate readings (1 and 2 h) post-administration in the sys-
temic study.
Microscopic examination of the pancreas
The pancreas was removed from each animal at the end of the
experiment and stored in 10 % formalin solution for micro-
scopic examination of islet of Langerhans cells. The tissues
were then processed and slides of 5-μm thickness were pre-
pared employing routine haematoxylin and eosin staining pro-
cedures (Falkeholm et al. 2001) (Fig. 1).
Statistical analysis
Data were expressed as means and were analyzed by one-way
ANOVA and Tukey’s multiple comparison post hoc test.
Mann-Whitney U test was applied to data where applicable.
Values were considered significant at P<0.05.
Results
Development of diabetes in streptozotocin-pretreated
animals
As disclosed in Fig. 2, animals administered streptozotocin
manifested diabetic symptoms reproducibly by increasing
the group mean blood glucose level from 91.0±1.7 mg/dL
on day 0 to 342.6±8.0 mg/dL on the fifth day, 350.1±
8.8 mg/dL on day 15, and 383.3±9.3 mg/dL on day 29 of
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the experimental schedule. However, at a streptozotocin dose
of 50mg/kg (Field et al. 1999), animals exhibitingmean blood
glucose levels ≥270 mg/dL on day 5 were selected for the
study (Jolivalt et al. 2006). Development of diabetes was fur-
ther confirmed from the degradation of pancreatic islet cells in
streptozotocin-pretreated diabetic rats (Fig. 1). In addition to
hyperglycaemia, diabetic animals exhibited mild polyphagia,
polydipsia and polyuria and some body weight loss (Fig. 3).
Activity of topical gabapentin gel (10 %) and systemic
gabapentin (75 mg/kg i.p.) on static allodynia in female
diabetic rats
The pooled mean von Frey filament pressures (g±SD) calcu-
lated as PWT values (static allodynia) are plotted in Fig. 4. In
the topical application experiments (Fig. 4a), the treatment
groups consisted of saline, gabapentin gel alone (GG),
streptozotocin pretreatment alone (STZ), and streptozotocin
pretreatment plus either topical gabapentin gel (STZ + GG
10 %) or topical control gel (STZ + CG) (F(4,31)=36.41,
P<0.001). Tukey’s post hoc analysis revealed a significant
decrease (P<0.001) in the PWT responses of streptozotocin-
pretreated animals versus saline-treated controls, and this was
reversed in the group pretreated with streptozotocin and then
treated with topical gabapentin gel (STZ + GG, P<0.001).
There were also increased PWT values for both gabapentin
gel (P<0.001) and control gel vehicle (P<0.001) topical treat-
ments compared to the streptozotocin-pretreated control
(STZ) group (Fig. 4a).
Fig. 2 The effect of streptozotocin (STZ, 50 mg/kg i.p.) or saline vehicle
on blood glucose levels of rats (mean±SEM) measured on days 0, 5, 15
and 29 of the experimental protocol. Values for streptozotocin-treated
animals were significantly different compared to saline-vehicle-treated
controls (***P<0.001, Mann–Whitney U test). The animal selection
level for subsequent allodynia studies was ≥270 mg/dL on day 5
Fig. 1 Photomicrographs of the pancreas from rats treated with a saline
or b streptozotocin (50 mg/kg) i.p. showing intact or degenerated islets of
Langerhans, respectively, 29 days after treatment
Fig. 3 Effect of streptozotocin (STZ, 50 mg/kg i.p.) or saline vehicle on
rat body weights (mean±SEM) measured on days 0, 5, 15 and 29 of the
experimental protocol. Values for streptozotocin-treated animals were
significantly different compared to saline-vehicle-treated controls
(***P<0.001, Mann–Whitney U test)
Naunyn-Schmiedeberg's Arch Pharmacol (2015) 388:1129–1140 1133
In the systemic study, the mean pooled von Frey filament
pressures (g) calculated as PWT values (static allodynia) were
graphed. The four groups consisted of saline controls,
gabapentin alone (GP 75 mg/kg i.p), streptozotocin
pretreatment alone (STZ) and streptozotocin plus gabapentin
(STZ + GP (75 mg/kg i.p.) (F(3,16)=15.92, P<0.001)
(Fig. 4b). Tukey’s post hoc analysis test revealed a decrease
(P<0.001) in the PWT response to streptozotocin pretreat-
ment versus saline-treated controls. A reversal of this
streptozotocin-decreased PWToccurred when combined with
systemic gabapentin (STZ + GP, P<0.01) at the pooled 1 and
2-h post-treatment times, whereas gabapentin alone induced a
response that was greater than streptozotocin alone (P<0.05)
(Fig. 4b).
Activity of topical gabapentin gel (10 %) and systemic
gabapentin (75 mg /kg i.p) on dynamic allodynia in female
diabetic rats
Dynamic allodynia was assessed by lightly brushing a cotton
bud over the plantar surface of the hind paw of rats, and the
pooled PWL (mean s±SD) was determined (F(4,34)=13.99,
P<0.001) and plotted as shown in Fig. 5a. There was a sig-
nificant decrease in PWL caused by streptozotocin pretreat-
ment in comparison with the saline-treated controls
(P<0.001). This reduced PWL induced by streptozotocin
was totally reversed by combination with topical gabapentin
gel (STZ + GG, P<0.001) and also somewhat unpredictably
by the control gel (STZ + CG, P<0.001).
In the systemic study, dynamic allodynia was assessed
using the same protocol. PWL (mean s±SD) with respect to
time after treatment at the grouped 1 and 2-h intervals (F(3,
16)=15.92, P<0.001) is depicted in Fig. 5b. Streptozotocin
pretreatment reduced the PWL compared to saline treatment
(P<0.001), and this was reversed by combination with sys-
temic gabapentin administration (STZ + GP, P<0.01). How-
ever, as might be expected, there was also a statistical differ-
ence between the group treated with gabapentin alone (GP)
compared with those pretreated with streptozotocin (P<0.05,
Fig. 5b).
Activity of topical gabapentin gel (10 %) and systemic
gabapentin (75 mg/kg i.p) on static vulvodynia in female
diabetic rats
The mean von Frey filament force (g±SD) required to induce
an FRT (static vulvodynia) was calculated and then plotted for
the five treatment groups at the three merged daily application
times (F(4,46)=7.920, P<0.001) shown in Fig. 6a. ANOVA
coupled with Tukey’s post hoc analysis revealed a significant
reduction in the FRT force expressed after streptozotocin pre-
treatment compared to the saline-treated group (P<0.05). This
decrease was reversed in the group treated with the
streptozotocin plus topical gabapentin gel combination
(P<0.05) but not in those animals pretreated with
streptozotocin plus subsequent control gel. The gabapentin-
gel-alone group (GG) did display a difference from animals
Fig. 4 The static antiallodynia activity of topical gabapentin gel (10 %)
and systemic gabapentin (75 mg/kg i.p.) in streptozotocin-induced female
diabetic rats. Scatter plots showing mean paw withdrawal thresholds
(PWTs, g±SD) in response to von Frey filaments were determined in
all groups. a Topical gabapentin gel (10 %) alone without streptozotocin
pretreatment (triangle, GG, n=8), streptozotocin pretreatment followed
by control gel (inverted triangle, STZ + CG, n=9) or streptozotocin
pretreatment followed by gabapentin gel (diamond, STZ + GG, n=5)
was applied on the plantar surface of the right hind paws of rats for three
times daily and PWTwas measured 1 h after application. Significance of
differences in PWT is shown between topical saline (white circle, n=15)
and streptozotocin pretreatment (white square, STZ, n=6; ###P<0.001)
and between streptozotocin pretreatment (white square, STZ, n=6) versus
gabapentin gel alone (triangle, GG, n=8; ***P<0.001), streptozotocin
pretreatment with control gel (inverted triangle, STZ + CG, n=9;
***P<0.001) and streptozotocin pretreatment plus gabapentin gel
(diamond, STZ + GG, n=5; ***P<0.001), ANOVA followed by Tukey’s
post hoc test. b In the case of the systemic study, gabapentin (75 mg/kg)
was administered intraperitoneally (i.p.) and PWT was measured using
the same protocol as gabapentin gel. ANOVA followed by Tukey’s post
hoc test revealed statistical differences in PWT between saline (white
circle, n=15) and streptozotocin pretreatment (white square, STZ, n=6;
###P<0.001), between streptozotocin pretreatment (white square, STZ,
n=6) and gabapentin alone (triangle, GP 75 mg/kg, n=5; *P<0.05) and
also between streptozotocin plus gabapentin (inverted triangle, STZ +GP
75 mg/kg, n=8; **P<0.01)
1134 Naunyn-Schmiedeberg's Arch Pharmacol (2015) 388:1129–1140
receiving streptozotocin pretreatment (P<0.05) which was not
unexpected (Fig. 6a).
In the systemic gabapentin study, mean von Frey filament
pressures (g) calculated as FRT values (static vulvodynia) were
plotted for treatment groups at the pooled 1 and 2-h intervals
(F(3,20)=51.02, P<0.001) shown in Fig. 6b. There was a signif-
icant reduction of FRT in the group pretreated with
streptozotocin (STZ) compared to the saline-administered group
(P<0.001). This action was reversed in the group that received
streptozotocin pretreatment plus ensuing gabapentin (STZ +GP,
P<0.001). In addition, there was a difference in FRT between
Fig. 6 The static antivulvodynia effect of gabapentin gel (10 %) and
systemic gabapentin (75 mg/kg i.p.) in streptozotocin-induced diabetic
female rats. Scatter plots showing mean von Frey filament force
flinching response thresholds (FRTs, g±SD) were determined in all
groups (n=animal group numbers meeting the inclusion criteria are
shown in brackets). a Topical control gabapentin gel (10 %) alone
without streptozotocin pretreatment (triangle, GG, n=8) or
streptozotocin pretreatment with either control gel (inverted triangle,
STZ + CG, n=13) or with gabapentin gel (diamond, STZ + GG, n=14)
was applied on the anogenital area including mons pubis of rats for three
times daily and responses were measured 1 h after application.
Significance of differences in FRT is shown between topical saline
control (white circle, n=15) and streptozotocin pretreatment (white
square, STZ, n=8; #P<0.05) and between streptozotocin pretreatment
(white square, STZ, n=8) versus gabapentin gel alone (triangle, GG,
n=8;*P<0.05), streptozotocin pretreatment followed by control gel
(inverted triangle, STZ + CG, n=13; *P>0.05) and streptozotocin
pretreatment followed by gabapentin gel (diamond, STZ + GG, n=14;
*P<0.05) application, ANOVA followed by Tukey’s post hoc test. b In
the systemic study, mean von Frey filament force flinching response
thresholds (FRTs, g±SD) were determined in all groups, and
gabapentin (triangle, GP, 75 mg/kg, n=8) was administered i.p. The
responses were measured post-treatment. Statistical significance of
differences in FRT is shown between saline control (white circle, n=15)
and streptozotocin pretreatment (white square, STZ, n=8; ###P<0.001)
and between streptozotocin pretreatment (white square, STZ, n=8) and
gabapentin alone (triangle, GP, n=8; *P<0.05), and also from
streptozotocin combined with gabapentin (STZ + GP, inverted triangle,
n=6) post-drug treatment (***P<0.001), ANOVAwith Tukey’s post hoc
analysis test
Fig. 5 The dynamic antiallodynia activity of gabapentin gel 10 % and
systemic gabapentin (75 mg/kg i.p.) in streptozotocin-induced female
diabetic rats. Scatter plots showing mean paw withdrawal latency
(PWL, s±SD) in response to light brushing were determined in all
groups (n=animal group numbers meeting the inclusion criteria are
shown in brackets). a Topical control gabapentin gel alone without
streptozotocin treatment (triangle, GG, n=8), streptozotocin pretreatment
followed by gabapentin gel (10 %) (diamond, STZ + GG, n=10) or
streptozotocin pretreatment followed by control gel (inverted triangle,
STZ + CG, n=7) was applied on the plantar surface of the right hind
paw of rats for three times daily and PWL was measured 1 h after appli-
cation. Significance of differences in PWL is shown between topical
saline (white circle, n=15) and streptozotocin pretreatment (white square,
STZ, n=6, ###P<0.001) and between streptozotocin pretreatment (white
square, STZ, n=6) versus gabapentin gel alone (triangle, GG, n=8,
***P<0.001), streptozotocin treatment followed by control gel, i.e.
STZ + CG (inverted triangle, n=7; ***P<0.001) and streptozotocin
treatment followed by gabapentin gel, i.e. STZ + GG (10 %) (diamond,
n=10; ***P<0.001), ANOVA followed by Tukey’s post hoc test. b In the
case of the systemic study, the same protocol as topical gabapentin was
used but gabapentin (triangle, GP, 75 mg/kg) was administered i.p. and
PWL was measured. Statistical significance of differences in PWL is
shown between saline (white circle, n=15) and streptozotocin control
(white square, STZ, n=6) (###P<0.001) and between streptozotocin
control (white square, STZ, n=6) and gabapentin alone (triangle, GP,
n=8; *P<0.05) and STZ + GP 75 mg/kg (inverted triangle, n=5;
**P<0.01)
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the group administered gabapentin alone (GP) versus STZ pre-
treatment (P<0.05) and this is presented in Fig. 6b.
Activity of topical gabapentin gel (10 %) and systemic
gabapentin (75 mg/kg i.p) on dynamic vulvodynia
in female diabetic rats
As depicted in Fig. 7a, the FRL in seconds (dynamic
vulvodynia) from the rat anogenital area (vulva) to light
brushing was determined in the morning, noon and afternoon
pooled groups and then graphed (F(4,35)=31.14, P<0.001).
The latency values following saline control treatment were
reduced in the streptozotocin-pretreated group (STZ)
(P<0.001) and subsequently reversed by combined topical
gabapentin gel application (STZ + GG, P<0.001). In the
group treated with control gel along with streptozotocin pre-
treatment (STZ + CG), there was no difference noted in com-
parison with streptozotocin-alone pretreatment (STZ). More-
over, topical gabapentin gel by itself (GG) produced virtually
no change in FRL compared to the saline controls, the latency
values additionally being significantly greater than in animals
pretreated with streptozotocin (P<0.001, Fig. 7a).
In the systemic study, the FRL values (dynamic
vulvodynia) were plotted for merged groups at 1 and 2-h treat-
ment intervals (F(3,20)=51.02, P<0.001). The outcome re-
vealed a significant difference between the latency following
saline control treatment which was reduced by streptozotocin
pretreatment (STZ) (P<0.001) and subsequently reversed by
combined systemic gabapentin treatment (STZ + GP,
75 mg/kg, P<0.001) as shown in Fig. 7b. In addition, the
gabapentin-alone treatment group (GP, 75 mg/kg) displayed
greater FRL values (P<0.05) than the STZ-pretreated controls
in the protocol (Fig. 7b).
Discussion
Diabetic neuropathy is a common and serious complication
stemming frommetabolic abnormalities (Elliott 1994) causing
lesions of the peripheral and/or central nervous system leading
to sensory signs and symptoms (Backonja 2003). It is charac-
terized by progressive chronic neuropathic pain that is tingling
and burning in nature with hyperesthesia and paresthesia with
deep aching and it is increased by touch (Krause and Backonja
2003). It is greater at night (Boulton et al. 2005) and occurs in
the feet and lower legs and may involve the hands (Vinik et al.
2000) affecting patient sleep, mood, self-esteem, social life
(Said 2007) and ability to work (Vileikyte et al. 2003). Neu-
ropathic pain is often associated with allodynia, which is a
distinct feature and represents an abnormal pain to a stimulus
that does not normally provoke pain (Merskey 1986). It has
also been reported that small unmyelinated and large myelin-
ated primary nerves (Aβ and small-diameter nociceptive
fibres) are implicated in allodynia (Field et al. 1999).
Vulvodynia has features which are characteristic of other
chronic neuropathic pain conditions. These include the persis-
tent and burning quality of the pain, the allodynia and
hyperpathia, the absence of physical findings other than ery-
thema on examination, and the patient’s obsession with the
pain (Ben-David and Friedman 1999).
Fig. 7 The dynamic antivulvodynia effect of gabapentin gel 10 % and
systemic gabapentin (75 mg/kg i.p.) in streptozotocin-induced female
diabetic rats. Scatter plots showing mean flinching response latency
(FRL, s±SD) from the anogenital area (vulva) in response to light
brushing determined in all groups (n=animal group numbers meeting
the inclusion criteria are shown in brackets). a Topical control
gabapentin gel alone (triangle, GG, n=8), streptozotocin pretreatment
followed by gabapentin gel (10 %) (diamond, STZ + GG, n=8) or
streptozotocin pretreatment followed by control gel (inverted triangle,
STZ + CG, n=8) was applied to the anogenital area (vulva) of rats for
three times daily and FRL was measured 1 h after application.
Significance of differences in FRL is shown between topical saline
control (white circle, n=15) versus streptozotocin pretreatment (white
square, STZ, n=8; ###P<0.001), gabapentin gel alone versus
streptozotocin pretreatment (GG, triangle, n=8; ***P<0.001) and
streptozotocin pretreatment followed by gabapentin gel (STZ + GG,
diamond, n=8, ***P<0.001), ANOVAwith post hoc Tukey’s test. b In
the systemic study, the flinching response latency (FRL) was determined
in each group using the same protocol as for gabapentin gel and this was
plotted against treatment groups. The FRL was measured for gabapentin
(triangle, GP, 75 mg/kg i.p.). ANOVA with Tukey’s post hoc analysis
revealed significant differences in FRL between either the control
gabapentin-alone group (triangle, GP, 75 mg/kg, n=8; *P<0.05) or the
saline controls (white circle, n=15) and streptozotocin controls (white
square, STZ, n=8; ###P<0.001). There were subsequent increases in
FRL caused by gabapentin following streptozotocin pretreatment
(inverted triangle, STZ + GP, n=6; ***P<0.001)
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Experimental diabetes mellitus can be induced by most
commonly employed diabetogenic agents, i.e. alloxan and
streptozotocin. However, streptozotocin-induced diabetes
mellitus is used as a model for hyperalgesia (Bishnoi et al.
2011). Therefore, in this study, a diabetic neuropathic pain
model of allodynia and vulvodynia was employed involving
a single injection of streptozotocin (50 mg/kg) in female rats.
Since streptozotocin exhibits a stability problem (Rakieten
et al. 1963), fresh solutions were prepared at the time of ad-
ministration, and diabetes was confirmed by resultant degen-
erative changes in the pancreatic islets of Langerhans (Fig. 1).
Early neuropathic symptoms in streptozotocin-induced di-
abetic rodents have been reported including allodynia and
decreased nerve function velocity as well as axonal dystrophy
following electron microscopical analysis (Cameron et al.
1994, 1999; Li et al. 2004; Weiss et al. 1995). Moreover, later
symptoms of streptozotocin neuropathy, some of which are
similarly insulin reversible, have been well documented and
consist of hypoalgesia, large sensory nerve fibre pathology
comprising demyelination, degeneration and Schwann cell
damage and regeneration (Calcutt et al. 2004; Muller et al.
2008; Shaikh and Somani 2011; Vasconcelos et al. 2011;
Weiss et al. 1995). Furthermore, in streptozotocin-treated rats,
bladder afferent pudendal neurons located in the L6 and S1
dorsal root ganglia (McKenna and Nadelhaft 1986) have been
reported to be smaller in cross-sectional area in streptozotocin-
induced diabetics than in normal animals (Steers et al. 1994)
indicating axonopathy (Chen et al. 2013).
The current management approach to vulvodynia is redo-
lent of neuropathic pain treatment, usually involving adjunc-
tive therapy since monotherapy often fails to yield an effective
response. Pharmacological and non-pharmacological inter-
ventions include oral and topical medications, local and re-
gional injections, cognitive therapy, physical therapy and sur-
gery (Andrews 2010; Bates and Timmins 2002). Literature
reports regarding evidence of efficacy for pain reduction by
pharmacological intervention of generalized unprovoked
vulvodynia vary from fair to poor. The majority of these re-
ports lack high-quality evidence (Andrews 2010). However,
adequate substantiation of efficacy has been reported for
xylocaine (5 %), oral pregabalin, oral or topical gabapentin,
oral duloxetine and selective serotonin reuptake inhibitors
(SSRIs). Moreover, there is evidence of poor efficacy for top-
ical capsaicin, nitroglycerin, oral tricyclic antidepressants or
venlafaxine, pentosan polysulfate, opioids, tramadol, carba-
mazepine, lamotrigine, oxcarbazepine, topiramate and
valproic acid (Andrews 2010; Fischer 2004; Phillips and
Bachmann 2010). Based on these promising case reports
and retrospective investigations previously performed on
allodynia and vulvodynia, it was decided to conduct systemic
and topical gabapentin studies in order to validate
streptozotocin-induced diabetes as an animal model of
vulvodynia.
Arising from a pilot study, the streptozotocin-administered
animals were kept under strict observation for 29 days to de-
velop robust symptoms of static and dynamic allodynia and
vulvodynia in the animal model. The inclusion criteria for
animals in each group are depicted in Table 1. Static allodynia
and vulvodynia were present in some of the animals within
15 days following streptozotocin injection, while both dynam-
ic allodynia and vulvodynia were detected in most subjects
within 29 days post-streptozotocin injection. Overall assess-
ment at different times indicated that there were exclusions of
animals at different stages up to protocol day 29 in order to
achieve the criteria for the paradigm. The streptozotocin-
treated animals also showed significant loss in body weight
(Fig. 3) with elevated blood glucose levels (i.e. above 270 mg/
dL) as compared to saline-vehicle-treated animals (Fig. 2). In
order to test for allodynia and vulvodynia, in the topical gel
study, the animals were divided into treatment groups: saline
control, streptozotocin pretreatment control, control
gabapentin gel alone without streptozotocin pretreatment,
streptozotocin pretreatment plus control gel vehicle and
streptozotocin pretreatment plus gabapentin gel (10 %). In
the case of systemic gabapentin (75 mg/kg) for allodynia
and vulvodynia, the animals were divided into saline control,
streptozotocin pretreatment control, gabapentin alone without
streptozotocin pretreatment and streptozotocin pretreatment
plus gabapentin treatment groups. Responses were measured
by application of von Frey filaments or light brushing with
cotton buds. Streptozotocin itself induced explicit static and
dynamic mechanical allodynia and vulvodynia in comparison
with saline-treated controls. This was evidenced by signifi-
cantly reduced von Frey filament force PWT, reduced PWL,
vulval FRT and FRL. Control and gabapentin gels were ap-
plied in the morning, noon and afternoon on the hind paws
and anogenital (vulva) area of animals, while gabapentin
(75 mg/kg) was administered intraperitoneally (i.p.) for sub-
sequent allodynia and vulvodynia testing, respectively. The
results showed that topically applied gabapentin gel was able
to ameliorate static and dynamic allodynia in the
streptozotocin-pretreated animals (Suppl Figs. 4a and 5a).
Systemic gabapentin administration showed similar outcomes
by alleviating static and dynamic allodynia as compared to
streptozotocin-pretreated controls (Suppl Figs. 4b and 5b). In
the case of static and dynamic vulvodynia, there was a statis-
tically significant reversal of streptozotocin-induced
vulvodynia of both types by topical gabapentin gel application
(Suppl Figs. 6a and 7a). Likewise, systemic gabapentin
against static and dynamic vulvodynia displayed significant
differences between the combined gabapentin/streptozotocin
and streptozotocin-alone group values reflecting symptom re-
versal (Suppl Figs. 6b and 7b). Vulvodynia is a chronic con-
dition; however, testing in the model was performed on day 29
in the protracted protocol and not on days 5 and 15 for the
purpose of avoiding intervening repeated-test stress induction.
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Consequently, the persistent quality of vulvodynia during this
interim period was not fully ascertained. Thus, systemic ad-
ministration of gabapentin has provided some evidence with
respect to validation of the current animal model for allodynia
and vulvodynia since this agent has exhibited efficacy not
only in animals (Carlton and Zhou 1998; Field et al. 1999)
but also in the clinic (Boardman et al. 2008; Gorson et al.
1999).
In the gabapentin topical study, there was an apparent
antiallodynia effect of the control gel seen in this investiga-
tion. This might derive from the finding that streptozotocin
induces epidermal thinning in the plantar surface of the rat
hind paw (Kadic et al. 2014), and the occlusive coating quality
of the xanthan gum hydrocolloid constituent (Marchitto and
Flock 2013) along with the polyacrylamide in the gel may
have acted as a physical barrier to mechanical stimuli applied
to the weakened paw surface. This is somewhat analogous to
the hydrocolloid gel in dressings which give rise to patients
experiencing less pain and the need for less analgesia in the
management of abrasive wounds (Heffernan and Martin
1994) or following skin shave biopsy (Nemeth et al. 1991).
Conversely, the lack of alleviation of static and dynamic
vulvodynia by the control gel may be a high-level sensory
consequence of the density of ventral and dorsal sensory nerve
branches emerging from the pudendal canal, respectively, to
the perineum (superficial perineal nerve) and genitalia (termi-
nal branch) (Robert et al. 1998). Furthermore, the inability of
gabapentin gel to show any significant antiallodynia activity
in comparison to control gel may be attributed to restricted
permeation of gabapentin from the gel formulation through
the paw skin. However, it is noteworthy that gabapentin de-
livered from control gel does penetrate human trunk skin
(PCCA 2012) although this particular skin area is likely to
be much thinner than that of the rat paw.
Gabapentin has been indicated for the treatment of neurop-
athy though the exact mechanism through which it inhibits
neuropathic pain still remains unclear. Evidence indicates that
gabapentin operates by increasing the level of gamma
aminobutaric acid (GABA) (Kocsis and Honmou 1994), by
acting as a non-N-methyl-D-aspartate (non-NMDA) receptor
antagonist (Chen et al. 2000; Kaneko et al. 2000) and by
inhibiting the α2δ1 subunit of voltage-gated calcium channels
(Gee et al. 1996; Shimoyama et al. 2000). Thus, gabapentin
could possibly reduce neuropathic signs via several potential
mechanisms. The efficacy for pain reduction by pharmacolog-
ical intervention of generalized unprovoked vulvodynia varies
from fair to poor (Andrews 2010). In this respect, the topical
formulation of gabapentin may be a useful addition to the
pharmacological treatment options available for neuropathic
pain syndromes. The topical gabapentin 10 % gel preparation
tested in this study is likely to possess minimal adverse effects
compared to those usually associated with systemic use of
gabapentin such as sedation, dizziness, somnolence, asthenia,
ataxia, amblyopia, headache and nausea (McLean et al. 2006).
This may be ascribed to the lower systemic concentration of
active ingredient delivered by the topical formulation than that
yielded by oral administration. Therefore, topical use of
gabapentin in the form of a gel could be a better alternative
for the clinical management of neuropathic pain syndromes
such as allodynia and vulvodynia.
Conclusions
In summary, these findings on the outcomes of topical and
systemic gabapentin in the diabetic neuropathy model of
vulvodynia tend to validate it as a useful non-clinical para-
digm. Nonetheless, the complex nature of the diabetic neuro-
pathic pain syndrome and the unpredictable rate of absorption
of gabapentin from the gel formulation warrant further re-
search to correlate any antivulvodynia activity of gabapentin
gel with gabapentin penetration after topical application. The
antivulvodynia action of gabapentin gel in the current model
also accords with retrospective clinical studies which conclud-
ed that topical gabapentin is well tolerated and associated with
significant pain relief in women with vulvodynia (Andrews
2010; Boardman et al. 2008).
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